.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Colorcon
Boehringer Ingelheim
US Department of Justice
US Army
Citi
Medtronic
Daiichi Sankyo
Cantor Fitzgerald
Harvard Business School
Moodys

Generated: September 24, 2017

DrugPatentWatch Database Preview

HETLIOZ Drug Profile

« Back to Dashboard

Which patents cover Hetlioz, and what generic Hetlioz alternatives are available?

Hetlioz is a drug marketed by Vanda Pharms Inc and is included in one NDA. There are six patents protecting this drug.

This drug has eighty-one patent family members in twenty-nine countries.

The generic ingredient in HETLIOZ is tasimelteon. One supplier is listed for this compound. Additional details are available on the tasimelteon profile page.

Summary for Tradename: HETLIOZ

Patents:6
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list21
Clinical Trials: see list2
Patent Applications: see list21
Drug Prices:see details
DailyMed Link:HETLIOZ at DailyMed

Pharmacology for Tradename: HETLIOZ

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Vanda Pharms Inc
HETLIOZ
tasimelteon
CAPSULE;ORAL205677-001Jan 31, 2014RXYesYes► Subscribe► Subscribe ► Subscribe
Vanda Pharms Inc
HETLIOZ
tasimelteon
CAPSULE;ORAL205677-001Jan 31, 2014RXYesYes► Subscribe► Subscribe► Subscribe
Vanda Pharms Inc
HETLIOZ
tasimelteon
CAPSULE;ORAL205677-001Jan 31, 2014RXYesYes► Subscribe► Subscribe ► Subscribe
Vanda Pharms Inc
HETLIOZ
tasimelteon
CAPSULE;ORAL205677-001Jan 31, 2014RXYesYes► Subscribe► Subscribe► Subscribe
Vanda Pharms Inc
HETLIOZ
tasimelteon
CAPSULE;ORAL205677-001Jan 31, 2014RXYesYes► Subscribe► Subscribe ► Subscribe
Vanda Pharms Inc
HETLIOZ
tasimelteon
CAPSULE;ORAL205677-001Jan 31, 2014RXYesYes► Subscribe► Subscribe ► Subscribe
Vanda Pharms Inc
HETLIOZ
tasimelteon
CAPSULE;ORAL205677-001Jan 31, 2014RXYesYes► Subscribe► SubscribeYY ► Subscribe
Vanda Pharms Inc
HETLIOZ
tasimelteon
CAPSULE;ORAL205677-001Jan 31, 2014RXYesYes► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: HETLIOZ

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,981,571 Benzodioxa alkylene ethers as melatonergic agents► Subscribe
2,017,087,122► Subscribe
6,060,506 Benzopyran derivatives as melatonergic agents► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: HETLIOZ

Country Document Number Estimated Expiration
Japan2016506410► Subscribe
Russian Federation2190609► Subscribe
World Intellectual Property Organization (WIPO)2014100292► Subscribe
China1239886► Subscribe
China104519877► Subscribe
Australia2015206797► Subscribe
Colombia7131366► Subscribe
Poland190499► Subscribe
Poland333950► Subscribe
Chile2014001993► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Teva
Accenture
Federal Trade Commission
Mallinckrodt
Johnson and Johnson
AstraZeneca
Citi
Express Scripts
Moodys
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot